What do Analysts Say about Aclaris Therapeutics, Inc.(NASDAQ:ACRS) & Plains Group Holdings, L.P.(NYSE:PAGP)

0
10

Aclaris Therapeutics, Inc. (ACRS) will report its next earnings on Feb 05 AMC. The company reported the earnings of $-1.06/Share in the last quarter where the estimated EPS by analysts was $-1.33/share. The difference between the expected and actual EPS was $0.27/share, which represents an Earnings surprise of 20.3%.

Many analysts are providing their Estimated Earnings analysis for Aclaris Therapeutics, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.99/share. These analysts have also projected a Low Estimate of $-1.04/share and a High Estimate of $-0.94/share.

In case of Revenue Estimates, 4 analysts have provided their consensus Average Revenue Estimates for Aclaris Therapeutics, Inc. as 3.46 Million. According to these analysts, the Low Revenue Estimate for Aclaris Therapeutics, Inc. is 2.23 Million and the High Revenue Estimate is 4.73 Million. The company had Year Ago Sales of 999 Million.

Some buy side analysts are also providing their Analysis on Aclaris Therapeutics, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Aclaris Therapeutics, Inc. might touch $50 high while the Average Price Target and Low price Target is $37.17 and $26 respectively.

Aclaris Therapeutics, Inc. closed its last trading session at $6.94 with the gain of 1.59%. The Market Capitalization of the company stands at 270.09 Million. The Company has 52-week high of $22.41 and 52-week low of $5.95. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.64% where SMA50 and SMA200 are -4.58% and -50.11% respectively. The Company Touched its 52-Week High on 03/12/18 and 52-Week Low on 01/18/19.

The Relative Volume of the company is 0.62 and Average Volume (3 months) is 575.17 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -55.6%. The Return on Equity (ROE) value stands at -62.8%. While it’s Return on Investment (ROI) value is -32.1%.

While looking at the Stock’s Performance, Aclaris Therapeutics, Inc. currently shows a Weekly Performance of 1.15%, where Monthly Performance is -8.56%, Quarterly performance is -42.4%, 6 Months performance is -59.13% and yearly performance percentage is -63.66%. Year to Date performance value (YTD perf) value is -4.6%. The Stock currently has a Weekly Volatility of 4.35% and Monthly Volatility of 5.20%.

Plains Group Holdings, L.P. (PAGP) will report its next earnings on Feb 05 AMC. The company reported the earnings of $0.87/Share in the last quarter where the estimated EPS by analysts was $0.35/share. The difference between the expected and actual EPS was $0.52/share, which represents an Earnings surprise of 148.6%.

Many analysts are providing their Estimated Earnings analysis for Plains Group Holdings, L.P. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $0.47/share. These analysts have also projected a Low Estimate of $0.24/share and a High Estimate of $0.61/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Plains Group Holdings, L.P. as 10.34 Billion. According to these analysts, the Low Revenue Estimate for Plains Group Holdings, L.P. is 7.76 Billion and the High Revenue Estimate is 13.57 Billion. The company had Year Ago Sales of 7.61 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for PAGP to be -21.7%. They are projecting Next Quarter growth of 100%. For the next 5 years, Plains Group Holdings, L.P. is expecting Growth of 26.81% per annum, whereas in the past 5 years the growth was -23.7% per annum.

Some buy side analysts are also providing their Analysis on Plains Group Holdings, L.P., where 3 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Plains Group Holdings, L.P. might touch $31 high while the Average Price Target and Low price Target is $27.92 and $24 respectively.

Plains Group Holdings, L.P. closed its last trading session at $23.29 with the loss of -0.99%. The Market Capitalization of the company stands at 3.63 Billion. The Company has 52-week high of $27.00 and 52-week low of $19.17. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.17% where SMA50 and SMA200 are 3.98% and -2.76% respectively. The Company Touched its 52-Week High on 08/10/18 and 52-Week Low on 12/27/18.

The Relative Volume of the company is 1 and Average Volume (3 months) is 1.91 million. The company’s P/E (price to earnings) ratio is 20.37 and Forward P/E ratio of 18.17.

The company shows its Return on Assets (ROA) value of -2.4%. The Return on Equity (ROE) value stands at -37.9%. While it’s Return on Investment (ROI) value is 8.9%.

While looking at the Stock’s Performance, Plains Group Holdings, L.P. currently shows a Weekly Performance of 0.96%, where Monthly Performance is -2.04%, Quarterly performance is 1.86%, 6 Months performance is -6.94% and yearly performance percentage is 12.49%. Year to Date performance value (YTD perf) value is 14.73%. The Stock currently has a Weekly Volatility of 2.58% and Monthly Volatility of 2.37%.

SHARE